TransMedics Group, Inc. — Director's Dealing 2019

May 2, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2019-05-01

Reporting Person: Provost Miriam (VP of US Regulatory & FDA Rel.)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$3.22	2028-04-05	Common Stock (28571)		Direct

Footnotes

F1: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date.

F2: As of the date of this Form 3, the Stock Option reported herein is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. will be converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. The number of shares in Column 3 reflects the Reporting Person's holdings following such conversion and the exercise price in Column 4 reflects the exercise price following such conversion.